A mixed methods study of age at diagnosis and diagnostic odyssey for Duchenne muscular dystrophy

被引:38
作者
Wong, Siaw H. [1 ,2 ]
McClaren, Belinda J. [1 ]
Archibald, Alison Dalton [1 ,2 ,3 ]
Weeks, Alice [1 ]
Langmaid, Tess [1 ]
Ryan, Monique M. [1 ,2 ,4 ]
Kornberg, Andrew [1 ,2 ,4 ]
Metcalfe, Sylvia A. [1 ,2 ]
机构
[1] Murdoch Childrens Res Inst, Parkville, Vic, Australia
[2] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia
[3] Victorian Clin Genet Serv, Parkville, Vic, Australia
[4] Royal Childrens Hosp, Dept Neurol, Parkville, Vic 3052, Australia
关键词
EXPERIENCES; EXPLORATION; THERAPY; PARENTS; BOYS;
D O I
10.1038/ejhg.2014.301
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The delayed diagnosis of Duchenne muscular dystrophy (DMD) may be an ongoing problem internationally. We aimed to ascertain age at diagnosis and explore parents' experiences of the diagnosis of DMD in Australia. Using mixed methods, data were collected from laboratory and clinical record audits of testing for DMD in Victoria and Tasmania, interviews and a national survey of parents regarding their experiences from first noticing symptoms to receiving a diagnosis. The audits revealed that the median age at diagnosis for DMD was 5 years (n = 49 during 2005-2010); this age had not changed substantially over this period. Fourteen parents interviewed reported age at diagnosis ranging from 2 to 8 years with a 6 month to 4 year delay between initial concerns about their child's development and receiving the DMD diagnosis. Sixty-two survey respondents reported the median age at diagnosis was 3 years and 9 months, while the median age when symptoms were noticed was 2 years and 9 months. Parents experienced many emotions in their search for a diagnosis and consulted with a wide range of health professionals. Half the survey respondents felt that their child could have been diagnosed earlier. Despite advances in testing technologies and increasing awareness of DMD, the age at diagnosis has remained constant in Australia. This mixed methods study shows that this diagnostic delay continues to have a negative impact on parents' experiences, places families at risk of having a second affected child and may have a deleterious effect on affected children's treatment.
引用
收藏
页码:1294 / 1300
页数:7
相关论文
共 50 条
  • [41] Questions Answered and Unanswered by the First CRISPR Editing Study in a Canine Model of Duchenne Muscular Dystrophy
    Wasala, Nalinda B.
    Hakim, Chady H.
    Chen, Shi-Jie
    Yang, N. Nora
    Duanl, Dongsheng
    HUMAN GENE THERAPY, 2019, 30 (05) : 535 - 543
  • [42] Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort
    Willcocks, Rebecca J.
    Rooney, William D.
    Triplett, William T.
    Forbes, Sean C.
    Lott, Donovan J.
    Senesac, Claudia R.
    Daniels, Michael J.
    Wang, Dah-Jyuu
    Harrington, Ann T.
    Tennekoon, Gihan I.
    Russman, Barry S.
    Finanger, Erika L.
    Byrne, Barry J.
    Finkel, Richard S.
    Walter, Glenn A.
    Sweeney, H. Lee
    Vandenborne, Krista
    ANNALS OF NEUROLOGY, 2016, 79 (04) : 535 - 547
  • [43] Effect of deflazacort on cardiac and sternocleidomastoid muscles in Duchenne muscular dystrophy: A magnetic resonance imaging study
    Mavrogeni, Sophie
    Papavasiliou, Antigoni
    Douskou, Marouso
    Kolovou, Genovefa
    Papadopoulou, Evangelia
    Cokkinos, Dennis V.
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2009, 13 (01) : 34 - 40
  • [44] Can in-the-moment diary methods measure health-related quality of life in Duchenne muscular dystrophy?
    Bray, Paula
    Bundy, Anita C.
    Ryan, Monique M.
    North, Kathryn N.
    QUALITY OF LIFE RESEARCH, 2017, 26 (05) : 1145 - 1152
  • [45] A 1-year analysis from a natural history study in Chinese individuals with Duchenne muscular dystrophy
    Li, Xihua
    Lv, Junlan
    Zhu, Wenhua
    Hong, Siqi
    Wang, Zhiqiang
    Chang, Xingzhi
    Gao, Ying Xu
    Zhou, Yangmei
    Jia, Caiping
    Fang, Jia
    Patterson, Terrell A.
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 42
  • [46] Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study
    Moretti, Antimo
    Liguori, Sara
    Paoletta, Marco
    Gimigliano, Francesca
    Iolascon, Giovanni
    ADVANCES IN THERAPY, 2022, 39 (07) : 3308 - 3315
  • [47] Mismatch Negativity Recording in Children With Duchenne Muscular Dystrophy: A Preliminary Study Integrating Neurophysiological and Neuropsychological Results
    Filippini, Melissa
    Guerra, Angelo
    Negosanti, Alessandra
    Santi, Sara
    Sarajlija, Jasenka
    Musti, Muriel Assunta
    Gobbi, Giuseppe
    Lassonde, Maryse
    Pini, Antonella
    JOURNAL OF CHILD NEUROLOGY, 2016, 31 (13) : 1468 - 1474
  • [48] Computerized working memory training in males with Duchenne muscular dystrophy: A single case experimental design study
    Hellebrekers, Danique M. J.
    Wirken, Jose M. A.
    Lionarons, Judith M.
    van Kuijk, Sander M. J.
    Klinkenberg, Sylvia
    Vles, Johan S. H.
    Hendriksen, Jos G. M.
    NEUROPSYCHOLOGICAL REHABILITATION, 2023, 33 (08) : 1325 - 1348
  • [49] Evaluation of fatigue and fatigability in people with Duchenne muscular dystrophy using a dynamic arm support - a pilot study
    Alberts, Lonneke
    Voet, Nicole
    Janssen, Mariska
    DISABILITY AND REHABILITATION-ASSISTIVE TECHNOLOGY, 2025, 20 (03) : 552 - 561
  • [50] Interplay of disability, caregiver impact, and out-of-pocket expenditures in Duchenne muscular dystrophy: a cohort study
    Schwartz, Carolyn E.
    Stark, Roland B.
    Borowiec, Katrina
    Audhya, Ivana F.
    Gooch, Katherine L.
    JOURNAL OF PATIENT-REPORTED OUTCOMES, 2022, 6 (01)